ストックスクリーナーアプリを入手
7.78
1.64%
-0.13
前日終値:
$7.91
開ける：
$7.87
24時間の取引高:
19,082
Relative Volume:
0.27
時価総額：
$439.34M
収益：
$154.57M
当期純損益:
$15.07M
株価収益率:
28.81
EPS:
0.27
ネットキャッシュフロー:
$10.92M
1週間 パフォーマンス:
+4.71%
1か月 パフォーマンス:
-2.14%
6か月 パフォーマンス:
+8.21%
1年 パフォーマンス:
+33.68%
1日の値動き範囲:
$7.78
$7.90
1週間の範囲:
$7.37
$7.91
52週間の値動き範囲:
$5.08
$9.155
Kamada Ltd Stock (KMDA) Company Profile
KMDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.78 | 439.34M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
152.82 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.85 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.33 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.41 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-21 | 開始されました | The Benchmark Company | Buy |
| 2024-07-03 | 開始されました | Stifel | Buy |
| 2018-02-02 | 開始されました | Chardan Capital Markets | Buy |
Kamada Ltd (KMDA) 最新ニュース
What drives Kamada Ltd. stock priceSpectacular growth rates - Autocar Professional
What analysts say about Kamada Ltd. stockExceptional growth trajectory - jammulinksnews.com
Is Kamada Ltd. a good long term investmentBreakthrough capital growth - jammulinksnews.com
What makes Kamada Ltd. stock price move sharplyHigh Potential Safe Trades - Newser
Kamada Ltd. Stock Analysis and ForecastOutstanding yields - jammulinksnews.com
Why Kamada Ltd. stock attracts strong analyst attentionFree Real-Time Trading Opportunities - Newser
How Kamada Ltd. stock performs during market volatilityProfitable Yet Secure Picks - Newser
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights - openPR.com
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - The Globe and Mail
Emphysema Pipeline 2025: MOA, ROA, And Clinical Trial Insights Explored By Delveinsight Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - MenaFN
Is Kamada (KMDA) Stock Undervalued Right Now? - Nasdaq
Kamada confirms continuous business operations despite recent events in Middle East - MSN
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Plasma Therapeutics Market Revenue to Attain USD 46.46 Bn by 2033 - Precedence Research
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Kamada Ltd (KMDA) 財務データ
収益
当期純利益
現金流量
EPS
3.25%
0.75%
大文字化:
|
ボリューム (24 時間):